400
Participants
Start Date
April 30, 2003
Primary Completion Date
June 30, 2005
Study Completion Date
June 30, 2005
pramlintide acetate
Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
Research Site, Anaheim
Research Site, Escondido
Research Site, La Jolla
Research Site, Los Gatos
Research Site, San Francisco
Research Site, Torrance
Research Site, New Britain
Research Site, Norwalk
Research Site, Norwich
Research Site, Washington D.C.
Research Site, Clearwater
Research Site, Orlando
Research Site, Columbus
Research Site, Honolulu
Research Site, Idaho Falls
Research Site, Indianapolis
Research Site, Vincennes
Research Site, Topeka
Research Site, Wichita
Research Site, Lexington
Research Site, Baltimore
Research Site, Bloomfield Hills
Research Site, Tupelo
Research Site, Las Vegas
Research Site, Reno
Research Site, Moorestown
Research Site, Neptune City
Research Site, Roseland
Research Site, New York
Research Site, Williston Park
Research Site, Yonkers
Research Site, Greenville
Research Site, Lakewood
Research Site, Westlake
Research Site, Portland
Research Site, Philadelphia
Research Site, Wilkes-Barre
Research Site, Charleston
Research Site, Sumter
Research Site, Chattanooga
Research Site, Knoxville
Research Site, Memphis
Research Site, Nashville
Research Site, Arlington
Research Site, Dallas
Research Site, Olympia
Research Site, Madison
Research Site, Milwaukee
Lead Sponsor
AstraZeneca
INDUSTRY